Apyx Medical outlines 9%–11% revenue growth target for 2026 as AYON launch accelerates (NASDAQ:APYX)

Management View - Apyx Medical Corporation reported a record revenue of $19.2 million for Q4 2025, marking a significant achievement for the company [2] - The revenue growth was primarily driven by a 38% increase in surgical aesthetics product sales, which reached $16.7 million, largely attributed to the launch of the AYON body contouring product [2] Future Outlook - Apyx Medical has set a revenue growth target of 9%–11% for 2026, indicating confidence in the continued acceleration of the AYON product line [2]